eClinical Solutions Market Growing at a CAGR of 13.3% - Research Provides Detailed Analysis of Trends, Growth and Forecast

The eClinical Solutions Market is projected to reach USD 15.4 billion by 2026 from USD 8.3 billion in 2021 at a CAGR of 13.3%.

Increasing clinical research activities in emerging Asian countries;

Asian countries are emerging as key outsourcing destinations for clinical trials primarily due to the presence of a large and genetically diverse population, high chronic disease prevalence, and easily available low-cost outsourcing services. A significant number of clinical trials are outsourced to CROs based in China and India. The growing number of pharmaceutical companies in developing Asian countries such as China, India, Taiwan, and Korea has also opened up growth opportunities for the eClinical solutions market in this region. China is the key emerging market for pharma and biopharmaceutical companies. According to a survey, more than 1,000 clinical trials were conducted in 2019 in China as compared to 339 trials in 2015. Phase I trials top the list each year, amounting to 486 trials in 2019. Funding support from governments, private entities, and other non-profit organizations in the region is also expected to aid market growth in the next 5 to 10 years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=553&utm_source=openpr&utm_medium=referral

The Growth in the eClinical Solutions market can primarily be attributed to factors such as increasing operational costs and regulatory requirements associated with clinical research studies, government grants to support clinical trials, and growing R&D expenditure on drug development by pharma-biotech companies.

The companies have a large market spread across various countries in North America, Europe, Asia Pacific, and the Rest of the World.

Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Largely unknown before the outbreak began in Wuhan, China, in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. The clinical trials market is shifting toward digital ways of working, and the COVID-19 outbreak is likely to both accelerate this trend and drive long-term changes to historically accepted trial management norms. If virtual and remote working modes prove to be sustainable methods of conducting a trial, it can be a great opportunity for all eClinical solutions providers.

Cloud-based (SaaS) segment is projected to record the highest CAGR

Based on delivery mode, the global eClinical solutions market is segmented into web-hosted (on-demand), licensed enterprise (on-premises), and cloud-based (SaaS) solutions. In 2020, the web-hosted (on-demand) segment commanded the largest share of the global market. The increasing number of cloud-based clinical trial solutions in the market and the rising adoption of these solutions in clinical research studies (owing to advantages such as ease of integration, quicker deployment, and flexible scalability with a fixed monthly fee) are fueling the growth of the cloud-based Electronic Data Capture and Clinical Data Management Systems Market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=553&utm_source=openpr&utm_medium=referral

Phase III clinical trials is expected to register the highest growth during the forecast period

Based on clinical trial phase, the eClinical solutions market has been segmented into phase I, phase II, phase III, and phase IV trials. The phase III clinical trials segment accounted for the largest share of the market in 2020. The large share of this segment is attributed to the high demand for eClinical solutions for phase III trials due to the involvement of thousands of patients in this phase

CROs segment is estimated to record the highest CAGR in the forecast period.

Based on end user, the global eClinical solutions market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, consulting service companies, medical device manufacturers, hospitals, and academic research institutions. The pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the market in 2020. However, the CROs segment is estimated to record the highest CAGR (15.5%) in the next five years. The increasing number of CROs in developed as well as developing countries, and the rising instances of clinical trial outsourcing to specialized clinical research organizations are responsible for the high growth rate of this segment.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=553&utm_source=openpr&utm_medium=referral

North America to Witness Significant Growth from 2021 To 2026

In 2020, North America commanded the largest share of the eClinical solutions market. Increasing government grants to support clinical trials, continuous product development and new product launches by eClinical solution vendors, and growth in the number of partnerships for new drug development are further stimulating the demand for eClinical solutions in this region.

Some of the prominent players in this Electronic Data Capture and Clinical Data Management Systems Market are Oracle Corporation (US), Medidata Solutions, Inc. (US), Parexel International Corporation (US), BioClinica, Inc. (US), Signant Health (US), Datatrak International, Inc. (US), ERT (US), eClinical Solutions, Inc. (US), MaxisIT Inc. (US), Bio-Optronics, Inc. (US), Merge Healthcare Incorporated (US), and OmniComm Systems, Inc. (US)

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.